Ovarian Cancer - MSK SPECTRUM (MSK, Nature 2022)

Summary

Ovarian Cancer - MSK SPECTRUM (MSK, Nature 2022) is a study catalogued by cBioPortal DataHub under the cancer-type code hgsoc. EvidenceHelix groups it with gynecologic studies.

Study description

Multi-region, multi-modal profiling of 42 untreated high-grade serous ovarian cancer (HGSOC) tumor/normal pairs. This study reports an integrative analysis of mutational processes and their impact on the tumor microenvironment using single-cell RNA sequencing, whole-genome sequencing, targeted sequencing (MSK-IMPACT), digital histopathology and multiplexed immunofluorescence. The study is part of a prospective research program to understand the spatio-temporal determinants of HGSOC evolution, treatment and response (MSK SPECTRUM: Memorial Sloan Kettering - SPatio-temporal Evolution in Cancer TRaced Using Multimodalities).

Text as published in the source's study metadata.

Citation & PubMed

Vázquez-García, Uhlitz et al. Nature 2022

Linked PubMed records: PMID 36517593

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

msk_spectrum_tme_2022

Short name

SPECTRUM (MSK, 2022)

Source cancer-type code

hgsoc

Reference genome

not given

Source access groups

PUBLIC

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.

Citations

Vázquez-García, Uhlitz et al. Nature 2022

• PubMed record 36517593 ↗

Citation counts are not part of the source metadata and are not shown.

Related studies

• High-Grade Serous Ovarian Cancer (MSK, NPJ Genome Med 2021)

  Targeted Sequencing of 45 Serous Ovarian Cancer tumor/normal pairs from 45 patients.

  GynecologicMSK studiesSource code hgsocPubMed 1

• Ovarian Serous Cystadenocarcinoma (TCGA, Firehose Legacy)

  TCGA Ovarian Serous Cystadenocarcinoma. Source data from GDAC Firehose (http://gdac.broadinstitute.org/runs/stddata__2016_01_28/data/OV/20160128/). Previously known as TCGA Provisional.

  GynecologicTCGA Firehose LegacySource code hgsoc

• Ovarian Serous Cystadenocarcinoma (TCGA, Nature 2011)

  Whole exome sequencing of 489 high-grade serous ovarian adenocarcinoma tumor/normal pairs. The Cancer Genome Atlas (TCGA) (http://cancergenome.nih.gov/) Serous Ovarian Cancer project. 489 cases. Raw data via the TCGA…

  GynecologicTCGA (other releases)Source code hgsocPubMed 1

• Ovarian Serous Cystadenocarcinoma (TCGA, PanCancer Atlas)

  Ovarian Serous Cystadenocarcinoma TCGA PanCancer data. The original data is here (https://gdc.cancer.gov/about-data/publications/pancanatlas). The publications are here (https://www.cell.com/pb-assets/consortium/panca…

  GynecologicTCGA PanCancer AtlasSource code hgsocPubMed 12

• Cervical Cancer (MSK, Clin Cancer Res 2023)

  Targeted sequencing of 177 cervical tumors and their matched normal samples via MSK-IMPACT.

  GynecologicMSK studiesSource code cervixPubMed 1

• Endometrial and Ovarian Cancer (MSK, Nature Medicine 2024)

  Targeted sequencing of 33 endometrial and ovarian tumors and their matched normals via MSK-IMPACT.

  GynecologicMSK studiesSource code mixedPubMed 1

• Endometrial Cancer (MSK, 2018)

  MSK-IMPACT sequencing of 197 advanced-staged endometrial cancer tumor samples with matched normals, from 189 patients treated at MSK.

  GynecologicMSK studiesSource code ucecPubMed 1

• Endometrial Cancer (MSK, Cancer Discovery 2023)

  Targeted sequencing of 1882 endometrial cancers and their matched normals via MSK-IMPACT.

  GynecologicMSK studiesSource code ucecPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.